Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Cournil, Amandine ^a   Eymard Duvernay, Sabrina ^a   Diouf, Assane ^b   Moquet, Claire ^a   Coutherut, Julie ^c   Gueye, Ndèye Fatou Ngom ^b   Cames, Cécile ^a   Taverne, Bernard ^c   Bork, Kirsten ^a   Sow, Papa Salif ^b   Delaporte, Eric ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b Fann University Teaching Hospital   (Senegal)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; BONE DENSITY; CALCIUM INTAKE; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENEGAL; SMOKING HABIT; VIRUS LOAD; BODY MASS; CASE CONTROL STUDY; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; BONE DENSITY; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; SENEGAL; VIRAL LOAD;

EID: 84857131586     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031726     Document Type: Article

References (46)

1. Brown TT, Qaqish RB, (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165-2174.
2. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, et al. (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51: 937-946.
3. Triant VA, Brown TT, Lee H, Grinspoon SK, (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499-3504.
4. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, et al. (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6: e17217.
5. Guglielmi G, Scalzo G, de Terlizzi F, Peh WC, (2010) Quantitative ultrasound in osteoporosis and bone metabolism pathologies. Radiol Clin North Am 48: 577-588.
6. Hans D, Dargent-Molina P, Schott AM, Sebert JL, Cormier C, et al. (1996) Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 348: 511-514.
7. Hans D, Durosier C, Kanis JA, Johansson H, Schott-Pethelaz AM, et al. (2008) Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women. J Bone Miner Res 23: 1045-1051.
8. Khaw KT, Reeve J, Luben R, Bingham S, Welch A, et al. (2004) Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet 363: 197-202.
9. Moayyeri A, Kaptoge S, Dalzell N, Bingham S, Luben RN, et al. (2009) Is QUS or DXA better for predicting the 10-year absolute risk of fracture? J Bone Miner Res 24: 1319-1325.
10. Constant D, Rosenberg L, Zhang Y, Cooper D, Kalla AA, et al. (2009) Quantitative ultrasound in relation to risk factors for low bone mineral density in South African pre-menopausal women. Arch Osteoporos 4: 55-65.
11. Krieg MA, Barkmann R, Gonnelli S, Stewart A, Bauer DC, et al. (2008) Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 11: 163-187.
12. Desclaux A, Ciss M, Taverne B, Sow PS, Egrot M, et al. (2003) Access to antiretroviral drugs and AIDS management in Senegal. AIDS 17 (Suppl 3): S95-101.
13. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
14. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, et al. (2002) The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16: 1363-1370.
15. Landman R, Poupard M, Diallo M, Ngom Gueye NF, Diakhate N, et al. (2009) Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 8: 379-384.
16. Ndiaye S, Ayad M, (2005) Senegal Demographic and Health Survey 2005 Dakar, Senegal Ministry of Health and Prevention.
17. Dop M-C, Gomis M-C, Gourdon M, Lesauvage S, (2003) Outils d'enquête alimentaire par entretien- Elaboration au Sénégal Paris IRD Editions.
18. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, et al. (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19: 402-409.
19. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, et al. (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21: 617-623.
20. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, et al. (2006) HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 42: 1014-1020.
21. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J, (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917-1923.
22. Dolan SE, Kanter JR, Grinspoon S, (2006) Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91: 2938-2945.
23. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, et al. (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63-67.
24. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, et al. (2005) Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16: 1345-1352.
25. Bolland MJ, Grey AB, Gamble GD, Reid IR, (2007) Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 92: 4522-4528.
26. Reid IR, (2002) Relationships among body mass, its components, and bone. Bone 31: 547-555.
27. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, et al. (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 93: 861-868.
28. Melton IL, Marquez MA, Achenbach SJ, Tefferi A, O'Connor MK, et al. (2002) Variations in bone density among persons of African heritage. Osteoporos Int 13: 551-559.
29. Nam HS, Shin MH, Zmuda JM, Leung PC, Barrett-Connor E, et al. (2010) Race/ethnic differences in bone mineral densities in older men. Osteoporos Int 21: 2115-2123.
30. Aspray TJ, Prentice A, Cole TJ, Sawo Y, Reeve J, et al. (1996) Low bone mineral content is common but osteoporotic fractures are rare in elderly rural Gambian women. J Bone Miner Res 11: 1019-1025.
31. Vanderjagt DJ, Bond B, Dulai R, Pickel A, Ujah IO, et al. (2001) Assessment of the bone status of Nigerian women by ultrasound and biochemical markers. Calcif Tissue Int 68: 277-284.
32. Zebaze RM, Seeman E, (2003) Epidemiology of hip and wrist fractures in Cameroon, Africa. Osteoporos Int 14: 301-305.
33. Briot K, Kolta S, Flandre P, Boue F, Ngo Van P, et al. (2011) Prospective one-year bone loss in treatment-naive HIV+ men and women on single or multiple drug HIV therapies. Bone 48: 1133-1139.
34. Brown TT, McComsey GA, (2010) Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 15: 425-429.
35. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, et al. (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23: 817-824.
36. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
37. Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR, (2011) Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. J Clin Endocrinol Metab 96: 2721-2731.
38. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, et al. (2007) The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 8: 164-172.
39. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791-1801.
40. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51: 963-972.
41. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, et al. (2009) Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 200: 1746-1754.
42. Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, et al. (2003) Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 4: 337-346.
43. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, et al. (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51: 554-561.
44. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, et al. (2006) Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38: 893-897.
45. Fessel WJ, Hurley LB, (2003) Is HIV sequestered in bone? Possible implications of virological and immunological findings in some HIV-infected patients with bone disease. AIDS 17: 255-257.
46. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, et al. (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22: 395-402.